Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.85 |
| ▸ | BCL2 | P10415 | 17/20 | 0.85 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.85 |
| ▸ | BAD | Q92934 | 2/20 | 0.85 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.85 |
| ▸ | ASPH | Q12797 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17207018 | 0.93 | BCL2L1 (0.83) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| SCHEMBL29077589 | 0.92 | BCL2 (0.79) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| Navitoclax SCHEMBL29363785 | 0.92 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| Navitoclax SCHEMBL522847 | 0.92 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| Navitoclax SCHEMBL30255921 | 0.92 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| Navitoclax SCHEMBL10316178 | 0.92 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| Navitoclax SCHEMBL15005512 | 0.92 | BCL2L1 (1.00) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| SCHEMBL19244593 | 0.90 | BCL2 (0.76) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| SCHEMBL2022422 | 0.90 | BCL2L1 (0.96) | BCL2L1BCL2BCL2L2BADBCL2L11 | |
| SCHEMBL2022805 | 0.90 | BCL2L1 (0.94) | BCL2L1BCL2BCL2L2BADBCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642796-B2 | Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor | ABBVIE INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642796-B2 | Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor | ABBVIE INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20100310648-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | ABBOTT GMBH & CO. KG (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100310648-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | ABBOTT GMBH & CO. KG (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310648-A1 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR | BCL2, BCL2L2, BCL2L1 | BCL2L1 3/4885BCL2 1/4885BCL2L2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.